“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

Breast cancer is the most common malignancy among women globally, with an increasing incidence rate that poses a significant threat to women's health worldwide. Molecular typing aids in the precise classification and stratified treatment of breast cancer. The continuous development of immunotherapy and targeted therapy offers new treatment options for patients with different types. At the recent 2023 China Conference of Integrated Oncology (CCHIO 2023), "Tumor Watch" had the opportunity to interview Professor Zhang Jin from Tianjin Medical University Cancer Hospital at the venue. Professor Zhang discussed the current state of breast cancer research in China, reviewed the evolution of breast cancer treatment strategies, and shared insights into the precision treatment of patients with different types.
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Zhang Guiming from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.

Understanding and Managing Chronic Hepatitis B: The Importance of Detailed Assessment

Since the introduction of the first oral nucleos(t)ide analogs (NAs) lamivudine for the treatment of chronic hepatitis B (CHB)  in China in 1998, there has been a continuous effort over 25 years to explore various generations of drugs by medical, pharmaceutical, and technological researchers. The NA family has expanded to include entecavir, telbivudine, tenofovir disoproxil fumarate, tenofovir alafenamide, besifovir and so on. In particular, the latter four have become the mainstay for controlling hepatitis B virus (HBV). Additionally, long-acting interferons, when used in combination or sequentially with NAs, enhance the treatment's effectiveness, providing hope for reaching new heights in the cure of HBV.
CASH interview | Professor Jinghui Zhang: Monitoring clonal hematopoiesis in pediatric patients to help improve long-term prognosis

CASH interview | Professor Jinghui Zhang: Monitoring clonal hematopoiesis in pediatric patients to help improve long-term prognosis

Clonal hematopoiesis usually refers to myeloid cell proliferation caused by genetic mutations in hematopoietic stem cells, and is also the basis of the pathogenesis of various blood diseases; monitoring clonal hematopoiesis can enable early detection of hematological malignancies. At the 4th CASH held recently, Professor Jinghui Zhang from St. Jude Children's Research Hospital shared the report "Treatment-Related Clonal Hematopoiesis in Adult Survivors of Childhood Cancer". After the meeting, " Oncology Frontier-Hematology Frontier" specially invited Professor Jinghui Zhang to give an in-depth sharing on the treatment-related causes, monitoring value and long-term impact of clonal hematopoiesis.
IAS Hot Review | Professor Wang Hui: Second-line treatment choice for children with HIV infection — CHAPAS-4 clinical trial 96-week data

IAS Hot Review | Professor Wang Hui: Second-line treatment choice for children with HIV infection — CHAPAS-4 clinical trial 96-week data

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the recently concluded 12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 (Conference Abstract No.: OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Professor Wang Hui from the Affiliated Second Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital) to provide a brilliant review of this research.
ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections

Multi-drug resistant organisms (MDRO) are commonly found in bacteria such as Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. In recent years, the emergence and spread of MDRO have posed numerous challenges in clinical practice, with limited treatment options being one of the thorny issues. Beta-lactamase inhibitor combinations are essential in the clinical management of MDRO infections, among which Ceftolozane-Tazobactam (CT) and Ceftazidime-Avibactam (CZA) are frontline drugs for treating Multi-drug Resistant Pseudomonas aeruginosa (MDR-PA) infections. However, there is a lack of sufficient research data comparing the efficacy of these two drugs. At the recent IDWeek 2023 held in the United States, researchers presented a multicenter observational study (Abstract No: 1109) that compared the efficacy of CT and CZA in treating MDR-PA-induced bacteremia or pneumonia. " Infectious Disease Frontline" invited Dr. Junyan Qu, from West China Hospital of Sichuan University, to introduce and comment on this study.
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).
ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.